Market Pulse: U.S. equities ripped higher as Datadog’s 31% surge and Block Inc.’s surprise earnings beat set a bullish tone in tech and fintech. The rally carried deep into small caps even as Bitcoin revenue faltered for Block.
Key Movers: Datadog’s “Datadog’s stock jumps 31% on crushing earnings beat…” (SiliconANGLE News) and Block Inc. led the charge, while Intel’s all-time high chatter (“Intel Stock Hits All-Time High…” – Ghacks Technology News) kept chip names on watch.
Macro & Politics: Analysts from Coinjournal.net asked if Bitcoin’s drop to $79K amid Hormuz flashpoint hints at higher oil-driven volatility, underscoring the nexus of geopolitics and crypto flows.
What’s Next: Keep an eye on early trading reactions to the FDA’s priority review updates for Alzheimer’s treatments.
Unfiltered Market Commentary
Everyone’s missing that the Bitcoin dip isn’t just about Strait of Hormuz jitteriness but about unprecedented funding-rate pain—negative funding rates have hit a 10-year record according to CoinDesk’s “Bitcoin slips to $79,000, DOGE leads majors losses as negative funding rates set 10-year record.” That means whales are bleeding to hold shorts and longs alike, priming the tape for a hell of a squeeze when the dust settles.
Here’s a curveball: Datadog’s “Datadog’s stock jumps 31% on crushing earnings beat…” (SiliconANGLE News) has traders swooning over software resilience, yet The Trade Desk’s $689m revenue beat got overshadowed by its CSO’s move to OpenAI (Digiday). Those two lines of business couldn’t look more different—one’s growth clarity, the other a reminder that top talent is a mobile asset. If you’re chasing pure numbers without leadership stability, you’re flirting with heartbreak.
Trade accordingly: lighten positions in levered energy names ahead of potential supply shocks from the Strait of Hormuz; hedge against geopolitical ripples. Meanwhile, keep a starter stake in Datadog-style winners—just don’t bet heavy without killer exit triggers.
📈 Breaking Financial News
Block Inc rises 8% as Q1 gives ‘earnings surprise’ despite Bitcoin dip
Block’s Q1 earnings beat estimates despite Bitcoin revenue falling 26% on changing Bitcoin “trading dynamics” and reducing fees on Cash App transactions.
Datadog’s stock jumps 31% on crushing earnings beat, showing there’s still hope for software
Shares of the application monitoring software giant Datadog Inc. popped after it crushed Wall Street’s expectations with its first-quarter financial results today and followed up with strong guidance.
Block raises 2026 outlook after first-quarter earnings beat, accelerating gross profit growth
Shares of Block Inc. rose more than 8% in late trading today after the financial services company beat earnings expectations, accelerated gross profit growth and raised its full-year outlook on the back of a deepening artificial intelligence push.
The Trade Desks’ $689m revenue beat is blunted by the departure of CSO Jacobson to OpenAI
Samantha Jacobson's exit from The Trade Desk to OpenAI overshadows the DSP's Q1 earnings beat as it trumpets successes over walled gardens.
Intel Stock Hits All-Time High After Report of Apple Chip Manufacturing Talks
Intel shares rose as much as 15 percent on Tuesday to reach an all-time high after reports that Apple is in talks to outsource chip manufacturing.
Wall Street's Secret Crypto Accumulation Exposed
This protocol is fueling billions in transactions while most investors chase headlines… creating what could be the most asymmetric opportunity of 2025! Revealed: Get the name of Wall Street's favorite crypto for just $3 before it potentially skyrockets!
🔍 Market Analysis & Insights
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
BioArctic AB's partner Eisai today announced that the FDA has extended the review period by three months for the supplemental Biologics License Application covering a subcutaneous formulation as a starting dose in early Alzheimer’s disease.
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
BioArctic AB's partner Eisai today announced that the FDA has extended the review period by three months for the supplemental Biologics License Application covering a subcutaneous formulation as a starting dose in early Alzheimer’s disease.
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. announced that the FDA has extended the review period by three months for the supplemental Biologics License Application for subcutaneous lecanemab-irmb injection.
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. announced that the FDA has extended the review period by three months for the supplemental Biologics License Application for subcutaneous lecanemab-irmb injection.
Is Bitcoin’s drop to $79K a bear trap as Hormuz tensions escalate?
Bitcoin retreated amid clashes in the Strait of Hormuz and rising oil prices. Analysts argue that a limited appetite for full-scale escalation caps downside risk. Bulls aim for a rebound toward $82,000, but bears could target a breakdown below $78,000.
The Comeback of the Century: Wall Street Wrote Him Off…
But Elon’s $3 Trillion Comeback Could Begin Soon. Elon Musk was declared washed up and finished. But any day now, he could unveil a new technology that outshines Tesla, SpaceX, even PayPal… Details here.
💰 Investment Opportunities
Bitcoin slips to $79,000, DOGE leads majors losses as negative funding rates set 10-year record
Bitcoin pulled back from this week's $81,500 high after U.S. forces fired on Iranian targets, while crypto futures markets logged their 67th straight day of negative funding rates, the longest streak in a decade per K33 Research.
Presgera Claims Evaluated: Latest Scientific Investigation Reveals Fake Ingredients Side Effects Risk
Presgera scam or legit? Ingredients, neuropathy claims, side effects guidance, and refund terms evaluated from the official label.
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
Lipocine Inc., a biopharmaceutical company leveraging its proprietary technology platform, announced financial results for the first quarter ended March 31, 2026.
The Fifth Circuit Proves Abortion Is on the Ballot this November
A Fifth Circuit ruling this week puts abortion policy front and center for November, highlighting how domestic politics can sway health-care and consumer sentiment.
Qualcomm stock jumps 15% as AI partnership with OpenAI, new Snapdragon chips and strong earnings boost investor confidence
Qualcomm stock is gaining attention after strong growth in AI, smartphones and data centers. Investors are watching due to new chip launches, better earnings and future AI plans.
[Urgent] Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny startup into a massive giant and did it again with Tesla. Now, Elon could unveil his biggest breakthrough yet—and you can profit before the IPO. Click for urgent details.